Explore why bridging studies are critical for NTI generic drugs. Learn about stricter bioequivalence criteria, regulatory requirements from FDA/EMA, and the challenges in ensuring safety and efficacy for narrow therapeutic index medications.
Read More
Discover why generic medications cost significantly less than brand-name drugs. Learn about the Hatch-Waxman Act, bioequivalence, and how competition drives down healthcare costs for patients and insurers.
Read More
Learn how the FDA approves generic drugs under the Hatch-Waxman Act, including the ANDA process, bioequivalence requirements, patent challenges, and how this system keeps prescription costs low for millions of Americans.
Read More
Studies show that switching to generic NTI drugs like warfarin, phenytoin, and cyclosporine can lead to dangerous fluctuations in blood levels. While some patients adapt safely, others face seizures, rejection, or bleeding. Monitoring and caution are critical.
Read More